The ABPI welcomed the recent Innovation Ecosystem Programme Review, which signalled a significant step in further strengthening the UK health innovation landscape and improving the accessibility of breakthrough treatments to patients.
The Association of the British Pharmaceutical Industry (ABPI) has welcomed the new review into the Innovation Ecosystem Programme, which represents an essential step in safeguarding Britain’s health innovation system being one of the world’s leading ones. By streamlining the collaboration of the NHS, regulators, and the life sciences sector in order to create a healthcare system that is more effective and easier to access, this new review is designed for such ends.
Perhaps the most important takeaway of the review is that the innovation ecosystem needs to be slick and flexible. ABPI has been arguing for a framework of this sort, which it believes will increase patient access to new treatments but also help the life sciences sector in its pursuit to deliver transformative medicines to the NHS faster. The UK government has already made considerable investments into digital and data-driven healthcare initiatives. However, stakeholders believe that a review will catalyze further breakthroughs through an improvement in regulatory processes and greater agile collaboration.
ABPI Chief Executive, Richard Torbett, said: “This review fits into the bigger ambition of making the clinical research landscape better and life-changing treatments more widely adopted in the NHS. The future of the sector will require integration of innovation such as artificial intelligence, genomic medicine, and advanced therapies to continue the UK’s leadership in healthcare innovation.”.
Torbet further added that the ABPI is eagerly looking forward to working alongside the government and healthcare partners in implementing the recommendations coming from the review. By improving the regulatory environment and correcting systemic inefficiencies, the review is aiming to bring down barriers to patient access.
The government’s commitment to the Innovation Ecosystem is thus demonstrated in initiatives such as the £37.5 million investment in Digital Innovation Hubs, which is already yielding valuable health data for accelerating scientific discoveries. Going forward with the Innovation Ecosystem Programme, the ABPI hopes that these efforts would lead to faster access to life-saving treatments and that the UK would be a leader in health innovation.
